Literature DB >> 25367170

Dramatic Improvement in the Multifocal Positron Emission Tomography Findings of a Young Adult with Chronic Granulomatous Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.

Tomonari Shigemura1, Yozo Nakazawa2, Koichi Hirabayashi1, Norimoto Kobayashi1, Kazuo Sakashita1, Kazunaga Agematsu1,3, Kenichi Koike1.   

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects of nicotinamide adenine dinucleotide phosphate oxidase. Catalase-positive bacteria and fungi are phagocytosed, but persist within phagocytes, resulting in granulomatous inflammation. Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for CGD, HSCT sometimes leads to fatal outcomes related to the exacerbation of persistent infectious or post-infectious inflammatory diseases, particularly in adolescent and young adult patients with a history of recurrent infections and/or multiple granulomas in organs. Here, we present the case of a young adult with X-linked CGD in whom multiple lesions were found in lungs and lymph nodes on both computed tomography and positron emission tomography (PET) scans before allogeneic HSCT, but all the lesions disappeared only on PET scan 5 months after HSCT. Monitoring the activity of multiple pre-existing lesions with PET scan may be beneficial to adolescent and young adult CGD-patients undergoing allogeneic HSCT.

Entities:  

Keywords:  Chronic granulomatous disease; FDG-PET; bone marrow transplantation

Mesh:

Substances:

Year:  2014        PMID: 25367170     DOI: 10.1007/s10875-014-0113-5

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  10 in total

1.  Femoral osteomyelitis due to Cladophialophora arxii in a patient with chronic granulomatous disease.

Authors:  T Shigemura; K Agematsu; T Yamazaki; K Eriko; G Yasuda; K Nishimura; K Koike
Journal:  Infection       Date:  2009-08-07       Impact factor: 3.553

2.  Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-D-glucose in children with chronic granulomatous disease.

Authors:  T Güngör; I Engel-Bicik; G Eich; U V Willi; D Nadal; J P Hossle; R A Seger; H C Steinert
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

3.  Chronic granulomatous disease. Report on a national registry of 368 patients.

Authors:  J A Winkelstein; M C Marino; R B Johnston; J Boyle; J Curnutte; J I Gallin; H L Malech; S M Holland; H Ochs; P Quie; R H Buckley; C B Foster; S J Chanock; H Dickler
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

Review 4.  Genetic, biochemical, and clinical features of chronic granulomatous disease.

Authors:  B H Segal; T L Leto; J I Gallin; H L Malech; S M Holland
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

5.  Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results.

Authors:  Y Sugawara; D K Braun; P V Kison; J E Russo; K R Zasadny; R L Wahl
Journal:  Eur J Nucl Med       Date:  1998-09

Review 6.  Modern management of chronic granulomatous disease.

Authors:  Reinhard A Seger
Journal:  Br J Haematol       Date:  2008-02       Impact factor: 6.998

Review 7.  Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.

Authors:  Elena Soncini; Mary A Slatter; Laura B K R Jones; Stephen Hughes; Stephen Hodges; Terence J Flood; Dawn Barge; Gavin P Spickett; Graham H Jackson; Matthew P Collin; Mario Abinun; Andrew J Cant; Andrew R Gennery
Journal:  Br J Haematol       Date:  2009-02-16       Impact factor: 6.998

8.  Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.

Authors:  Tayfun Güngör; Pierre Teira; Mary Slatter; Georg Stussi; Polina Stepensky; Despina Moshous; Clementien Vermont; Imran Ahmad; Peter J Shaw; José Marcos Telles da Cunha; Paul G Schlegel; Rachel Hough; Anders Fasth; Karim Kentouche; Bernd Gruhn; Juliana F Fernandes; Silvy Lachance; Robbert Bredius; Igor B Resnick; Bernd H Belohradsky; Andrew Gennery; Alain Fischer; H Bobby Gaspar; Urs Schanz; Reinhard Seger; Katharina Rentsch; Paul Veys; Elie Haddad; Michael H Albert; Moustapha Hassan
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

Review 9.  Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

Authors:  Reinhard A Seger; Tayfun Gungor; Bernd H Belohradsky; Stephane Blanche; Pierre Bordigoni; Paolo Di Bartolomeo; Terence Flood; Paul Landais; Susanna Müller; Hulya Ozsahin; Justen H Passwell; Fulvio Porta; Shimon Slavin; Nico Wulffraat; Felix Zintl; Arnon Nagler; Andrew Cant; Alain Fischer
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.

Authors:  C Schuetz; M Hoenig; S Gatz; F Speth; U Benninghoff; A Schulz; K M Debatin; W Friedrich
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

  10 in total
  2 in total

1.  Utility of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in a child with chronic granulomatous disease.

Authors:  Gunjan Garg; Raphaella DaSilva; Avni Bhalakia; David M Milstein
Journal:  Indian J Nucl Med       Date:  2016 Jan-Mar

Review 2.  A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.

Authors:  Mohammad Vaezi; Maryam Souri; Seyed Amin Setarehdan; Amir Ali Hamidieh; Mohammad Reza Fazlollahi; Zahra Pourpak; Mohsen Badalzadeh; Shaghayegh Tajik; Seyed Alireza Mahdaviani; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.